Home | The power of patients
Scandinavian Health Company Insight
Scandinavian Health Ltd.
In this issue
NSF
Contents
Capsugel
Capsugel Company Insight
Christensella: the key to unlocking gut microbiome-based drug discovery?
Molnar Company Insight
Molnar-Institute
A costly oversight: the ongoing impact of the valsartan recall
Novo Nordisk Company Insight
Novo Nordisk
Where is the UK’s supply of Migraleve?
Dupont Pharmaceuticals
Discussing drug policy reform with psychedelics campaigner Amanda Feilding
LB Bohle Company Insight
LB Bohle
Charting the life and times of the EMA as it leaves London
Komtur Pharmaceuticals Company Insight
Komtur Pharmaceuticals
CBD: the myth, the magic and the real deal drugs
CBDepot Company Insight
CBDepot
In the age of AMR, does a nationalised drug company make sense? The case for and against
AtoZ-CRO Company Insight
AtoZ-CRO
How do cancer cells communicate and can it help us catch them?
HOF Sonderanlagenbau
HOF Sonderanlagenbau Company Insight
Buyers’ clubs: the first step toward universal UK access to Orkambi?
Sterigenics
Owen Mumford
Are we nearing the end of animal testing in pharma?
Zenatek
Barc Lab
A safer ride: the latest innovation in targeted cancer treatment
Abiogen Pharma
Mimotopes
Next issue
12/18/2019 00:00:00
Go to article:
Home | The power of patients
Go to article:
Scandinavian Health Company Insight
Go to article:
Scandinavian Health Ltd.
Go to article:
In this issue
Go to article:
NSF
Go to article:
Contents
Go to article:
Capsugel
Go to article:
Capsugel Company Insight
Go to article:
Christensella: the key to unlocking gut microbiome-based drug discovery?
Go to article:
Molnar Company Insight
Go to article:
Molnar-Institute
Go to article:
A costly oversight: the ongoing impact of the valsartan recall
Go to article:
Novo Nordisk Company Insight
Go to article:
Novo Nordisk
Go to article:
Where is the UK’s supply of Migraleve?
Go to article:
Dupont Pharmaceuticals
Go to article:
Discussing drug policy reform with psychedelics campaigner Amanda Feilding
Go to article:
LB Bohle Company Insight
Go to article:
LB Bohle
Go to article:
Charting the life and times of the EMA as it leaves London
Go to article:
Komtur Pharmaceuticals Company Insight
Go to article:
Komtur Pharmaceuticals
Go to article:
CBD: the myth, the magic and the real deal drugs
Go to article:
CBDepot Company Insight
Go to article:
CBDepot
Go to article:
In the age of AMR, does a nationalised drug company make sense? The case for and against
Go to article:
AtoZ-CRO Company Insight
Go to article:
AtoZ-CRO
Go to article:
How do cancer cells communicate and can it help us catch them?
Go to article:
HOF Sonderanlagenbau
Go to article:
HOF Sonderanlagenbau Company Insight
Go to article:
Buyers’ clubs: the first step toward universal UK access to Orkambi?
Go to article:
Sterigenics
Go to article:
Owen Mumford
Go to article:
Are we nearing the end of animal testing in pharma?
Go to article:
Zenatek
Go to article:
Barc Lab
Go to article:
A safer ride: the latest innovation in targeted cancer treatment
Go to article:
Abiogen Pharma
Go to article:
Mimotopes
Go to article:
Next issue